Iclepertin - Boehringer Ingelheim
Alternative Names: BI-425809Latest Information Update: 15 Jul 2024
At a glance
- Originator Boehringer Ingelheim
- Class Antipsychotics; Aza compounds; Fluorine compounds; Heterocyclic bicyclo compounds; Isoxazoles; Nootropics; Small molecules; Sulfones
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Schizophrenia
- Phase II Cognition disorders
Most Recent Events
- 05 Jun 2024 Boehringer Ingelheim completes a phase I trial (In volunteers) in Germany (PO) (NCT06070597)
- 25 Jan 2024 Boehringer Ingelheim initiates a phase I trial (In volunteers) in Germany (PO) (NCT06070597)
- 11 Dec 2023 Boehringer Ingelheim completes a phase I pharmacokinetic trial (In volunteers) in Germany (PO) (NCT05731895) (EudraCT2022-003418-35)